반응식
[OH:1][C@H:2]([CH3:7])[CH2:3][C:4]([OH:6])=O.O.OC1C2N=NNC=2C=CC=1.Cl.C(N=C=NCCCN(C)C)C.FC(F)(F)C(O)=O.[N:38]1([C:44]2[N:52]=[C:51]([C:53]3[CH:54]=[N:55][C:56]([NH2:59])=[N:57][CH:58]=3)[N:50]=[C:49]3[C:45]=2[N:46]=[C:47]([N:65]2[CH2:70][CH2:69][NH:68][CH2:67][CH2:66]2)[N:48]3[CH2:60][C:61]([F:64])([F:63])[F:62])[CH2:43][CH2:42][O:41][CH2:40][CH2:39]1>C(N(CC)CC)C.CN(C)C=O>[NH2:59][C:56]1[N:57]=[CH:58][C:53]([C:51]2[N:50]=[C:49]3[C:45]([N:46]=[C:47]([N:65]4[CH2:70][CH2:69][N:68]([C:4](=[O:6])[CH2:3][C@H:2]([OH:1])[CH3:7])[CH2:67][CH2:66]4)[N:48]3[CH2:60][C:61]([F:62])([F:64])[F:63])=[C:44]([N:38]3[CH2:39][CH2:40][O:41][CH2:42][CH2:43]3)[N:52]=2)=[CH:54][N:55]=1참가 물질
반응물 4
생성물 1
시약·촉매·용매 2
실험 절차
(R)-3-hydroxybutanoic acid (39 mg, 0.38 mmol), hydroxybenzotriazole hydrate (58 mg, 0.38 mmol), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (72 mg, 0.38 mmol), dimethylformamide (5 ml), triethylamine (161 μl) were added to 5-[6-morpholin-4-yl-8-piperazin-1-yl-9-(2,2,2-trifluoroethyl)-9H-purin-2-yl]pyrimidin-2-amine trifluoroacetate (200 mg, 0.29 mmol) and the resulting mixture was stirred for 15 hours. The reaction mixture was partitioned with ethyl acetate and saturated aqueous sodium bicarbonate solution, the organic layer was dried over magnesium sulfate, and then the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography (chloroform:methanol=19:1) to give the title compound (77 mg, 48%) as a colorless solid.
후처리
- customThe reaction mixture was partitioned with ethyl acetate and saturated aqueous sodium bicarbonate solution
- dry with materialthe organic layer was dried over magnesium sulfate
- customthe solvent was evaporated under reduced pressure
- customThe residue was purified by silica gel chromatography (chloroform:methanol=19:1)
출처 및 근거
- ORD 기록
- ord-f269c8902f3b4bd7aea0cd19018b98ef
- 출처 데이터셋
- uspto-grants-2012_01
- 특허 번호
- US08097622B2
연결된 노트
불러오는 중…